FILSPARI® Highlighted as First-Line IgA Nephropathy Treatment in New Guidelines by Carlisle Companies
- Updated guidelines endorse FILSPARI® as a potential first-line therapy for IgA Nephropathy management.
- FILSPARI's effectiveness is supported by robust clinical trial evidence, positioning it as a leading treatment option.
- The collaboration between CSL Vifor and Travere Therapeutics aims to enhance patient care in nephrology.
New Guidelines Elevate FILSPARI® as Key Treatment for IgA Nephropathy
In a significant development for the management of IgA Nephropathy (IgAN), CSL Vifor and Travere Therapeutics, Inc. endorse the updated 2025 clinical practice guidelines released by the Kidney Disease: Improving Global Outcomes (KDIGO). These guidelines aim to enhance the care of patients suffering from IgAN, focusing on critical aspects such as diagnostic criteria, treatment goals, and strategies to optimize patient outcomes. Among the notable recommendations is the emphasis on achieving remission of proteinuria—specifically targeting levels below 0.5 grams per day, ideally under 0.3 grams per day—as well as slowing the decline of estimated glomerular filtration rate (eGFR).
The updated guidelines signify a paradigm shift in treatment approaches, advocating for the use of FILSPARI® (sparsentan) as a potential first-line therapy for managing nephron loss due to IgAN. This Dual Endothelin Angiotensin Receptor Antagonist (DEARA) presents a compelling alternative to the traditional Renin-Angiotensin System inhibitor (RASi)-first strategy. Clinical trials, particularly the PROTECT trial, demonstrate FILSPARI's effectiveness, having enrolled more patients than all previous RASi trials combined. This robust evidence base positions FILSPARI as a frontrunner in improving kidney health outcomes for IgAN patients.
Experts in the field, such as Prof. Dr. med. Jürgen Floege from RWTH Aachen University Hospital, express optimism about these guidelines, noting that they mark a critical advancement for the IgAN community. The clarity provided by the updated recommendations empowers clinicians to make informed treatment decisions aimed at improving long-term kidney health. Dr. Achim Obergfell, Global Medical Lead at Travere Therapeutics, underscores the inclusion of FILSPARI in the guidelines as a validation of its favorable benefit-risk profile. This acknowledgment reflects a broader commitment to enhancing patient care and navigating the complexities of IgAN treatment effectively.
In addition to the endorsement of FILSPARI, the guidelines emphasize the necessity of individualized treatment plans and continuous monitoring of kidney function in IgAN patients. This patient-centric approach, in conjunction with the innovative treatment strategies outlined, aims to foster better health outcomes and provide a framework for clinicians to follow in managing this challenging condition. The ongoing collaboration between CSL Vifor and Travere Therapeutics exemplifies a unified effort toward advancing care in the field of nephrology.
Related Cashu News

Lockheed Martin Advances AI, Autonomy, and Space Exploration for Enhanced Military Operations and Safety
Lockheed Martin (Ticker: LMT) is making significant strides in integrating artificial intelligence and autonomy to enhance the efficiency and safety of military operations. The company focuses on deve…

AeroVironment Reports 133% Revenue Growth Amid Rising Military Demand for UAVs
AeroVironment (Ticker: AVAV) has emerged as a leader in the unmanned aerial vehicle (UAV) industry, particularly amidst a heightened global focus on defense technologies. The company has achieved subs…

AZZ Inc. Earnings Report Could Impact Stock Volatility and Dividend Investor Sentiment
AZZ Inc. (Ticker: AZZ) positions itself strongly in the industrial sector with its upcoming earnings report, reflecting its financial health and dividend strategy. Scheduled for release on July 8, the…

Astronics Signs Long-Term Deal with Vertical Aerospace for Valo eVTOL Power Systems
In late June 2026, Vertical Aerospace establishes a long-term agreement with Astronics Corporation (Ticker: ATRO) to supply the low-voltage power distribution system for its Valo eVTOL aircraft. This…

